Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
20 studies found for:    Open Studies | spectrum pharmaceuticals
Show Display Options
RSS Create an RSS feed from your search for:
Open Studies | spectrum pharmaceuticals
Need help? See RSS Feeds
Choose a feed type:
Show studies first received on any dateShow studies that were first received in the last 14 days
Show studies last updated date on any dateShow studies that were added or modified in the last 14 days
Rank Status Study
1 Not yet recruiting Pharmacokinetics of SPI-2012 (Eflapegrastim) in Breast Cancer Patients Receiving Docetaxel and Cyclophosphamide (TC) Chemotherapy
Conditions: Breast Cancer;   Pharmacokinetics
Intervention: Drug: SPI-2012
2 Not yet recruiting Trial of SPI-2012 Versus Pegfilgrastim in the Management of Chemotherapy Induced Neutropenia in Early- Stage BReast Cancer Patients Receiving Docetaxel and Cyclophosphamide (RECOVER)
Conditions: Neutropenia;   Breastcancer
Interventions: Drug: SPI-2012;   Drug: Pegfilgrastim;   Drug: Docetaxel;   Drug: Cyclophosphamide
3 Recruiting To Evaluate the Safety and Pharmacokinetics of Belinostat in Patients Who Have Wild-type, Heterozygous, and Homozygous UGT1A1*28 Genotypes
Conditions: Solid Tumors;   Hematological Malignancies
Interventions: Drug: Belinostat IV;   Drug: Belinostat
4 Recruiting To Evaluate Safety and Pharmacokinetics of Belinostat in Patients Who Have Mild, Moderate and Severe Renal Impairment.
Condition: Relapsed/Refractory Solid Tumors/Hematological Malignancies
Intervention: Drug: Belinostat
5 Recruiting Study of Poziotinib in Patients With HER2-Positive Metastatic Breast Cancer
Condition: Breast Cancer
Intervention: Drug: Poziotinib
6 Recruiting RAnDomized Trial of SPI-2012 Versus Pegfilgrastim in the Management of Chemotherapy Induced Neutropenia in Breast CANCEr Patients Receiving Docetaxel and Cyclophosphamide
Conditions: Neutropenia;   Breast Cancer
Interventions: Drug: SPI-2012;   Drug: Pegfilgrastim
7 Recruiting A Dose-Finding Study of Folotyn® (Pralatrexate Injection) Plus CHOP With Peripheral T-Cell Lymphoma (PTCL)
Condition: Peripheral T-Cell Lymphoma (PTCL)
Intervention: Drug: Pralatrexate Injection
8 Recruiting Phase 2, Single Arm, Open Label Study of Folotyn in Combination With Oral Leucovorin to Prevent or Reduce Mucositis in Patients With PTCL
Conditions: Relapsed Peripheral T-Cell Lymphoma;   Refractory Peripheral T-Cell Lymphoma
Interventions: Drug: Folotyn and Leucovorin;   Drug: Folic Acid;   Drug: Vitamin B12
9 Recruiting Zevalin Post-marketing Surveillance in Japan
Condition: Non-Hodgkin's Lymphoma (NHL)
Intervention: Drug: [90]Y-ibritumomab tiuxetan (Zevalin, BAY86-5128)
10 Not yet recruiting Propylene Glycol-Free Melphalan Hydrochloride (Evomela) in AL Amyloidosis Patients
Condition: Amyloidosis; Systemic
Intervention: Drug: Propylene Glycol-Free Melphalan Hydrochloride
11 Recruiting Vincristine Sulfate Liposome Injection (Marqibo®) in Combination With UK ALL R3 Induction Chemotherapy for Children, Adolescents, and Young Adults With Relapsed ALL
Conditions: ALL, Childhood;   Lymphoblastic Leukemia, Acute, Childhood;   Lymphoblastic Leukemia, Acute
Intervention: Drug: Marqibo in combination with UK ALL R3
12 Recruiting Zevalin Before Stem Cell Transplant in Treating Patients With Non-Hodgkin Lymphoma
Conditions: Refractory Non Hodgkin Lymphoma;   Relapsed Non Hodgkin Lymphoma
Interventions: Biological: rituximab;   Biological: ibritumomab tiuxetan;   Biological: anti-thymocyte globulin;   Radiation: total nodal irradiation;   Procedure: peripheral blood stem cell transplantation;   Procedure: allogeneic hematopoietic stem cell transplantation;   Drug: cyclosporine;   Drug: mycophenolate mofetil
13 Recruiting Hyper-CVAD With Liposomal Vincristine in Acute Lymphoblastic Leukemia
Condition: Leukemia
Interventions: Drug: Rituximab;   Drug: Imatinib;   Drug: Cyclophosphamide;   Drug: Doxorubicin;   Drug: Mesna;   Drug: VSLI;   Drug: Solu-Medrol;   Drug: Methotrexate;   Drug: Ara-C;   Drug: G-CSF;   Drug: Pegfilgrastim;   Drug: Dexamethasone
14 Recruiting Re-Induction Therapy for Relapsed Pediatric T-Cell Acute Lymphoblastic Leukemia or Lymphoma
Conditions: Acute Lymphoblastic Leukemia;   Lymphoma, Non-Hodgkin's;   Leukemia, T-Cell;   Leukemia, B-Cell
Interventions: Drug: Dexamethasone;   Drug: Panobinostat;   Drug: Liposomal vincristine;   Drug: Mitoxantrone;   Drug: Peg-asparaginase;   Drug: Bortezomib;   Drug: Intrathecal Triples;   Drug: High-dose methotrexate;   Drug: 6-Mercaptopurine;   Drug: High-dose cytarabine;   Drug: Nelarabine;   Drug: Cyclophosphamide;   Drug: Etoposide;   Drug: Clofarabine
15 Recruiting Poziotinib in EGFR Exon 20 Mutant Advanced Non-Small Cell Lung Cancer (NSCLC)
Conditions: Malignant Neoplasm of Respiratory and Intrathoracic Organ;   Non-Small Cell Lung Cancer
Intervention: Drug: Poziotinib
16 Recruiting Vincristine Sulfate Liposome in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
Condition: Recurrent Adult Acute Myeloid Leukemia
Interventions: Drug: Vincristine Sulfate Liposome;   Other: Laboratory Biomarker Analysis
17 Recruiting Vincristine Sulfate Liposome Injection (Marqibo®), Bendamustine and Rituximab—Phase I Trial in Indolent B-cell Lymphoma
Conditions: Lymphoma, Non-Hodgkin;   Lymphoma, Follicular;   Lymphoma, Mantle-Cell;   Lymphoma, Small-Cell;   Waldenstrom Macroglobulinemia;   Lymphoma, B-Cell, Marginal Zone
Interventions: Drug: Rituximab;   Drug: Bendamustine;   Drug: Vincristine sulfate liposome injection
18 Recruiting MRSI to Predict Response to RT/TMZ ± Belinostat in GBM
Condition: Glioblastoma Multiforme of Brain
Interventions: Radiation: Standard Radiation Therapy;   Drug: Standard Temozolomide;   Drug: Belinostat
19 Recruiting Behavioral Treatment of Adolescent Substance Use
Condition: Substance Use Disorders
Interventions: Behavioral: Behavior Therapy;   Behavioral: Working Memory Training
20 Recruiting Pheno- & Genotyping POF (WHO III)
Conditions: Premature Ovarian Failure (POF);   Incipient Ovarian Failure;   Poor Response After Ovarian Hyperstimulation;   Early Menopause;   Hypergonadotropic Amenorrhea
Intervention:

Study has passed its completion date and status has not been verified in more than two years.